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ABSTRACT
The risk associated with exposure to ionising radiation is dependent on the char-
acteristics of the exposed individual. The size and structure of the individual influences
the absorbed dose distribution in the organs. Traditional methods used to calculate the
patient organ doses are based on standardised calculation phantoms, which neglect the
variance of the patient size or even sex. When estimating the radiation dose of an indi-
vidual patient, patient specific calculation methods must be used. Methods for patient
specific dosimetry in the fields of X-ray diagnostics and diagnostic and therapeutic use
of radiopharmaceuticals were proposed in this thesis.
A computer program, ODS-60, for calculating organ doses from diagnostic X-ray
exposures was presented. The calculation is done in a patient specific phantom with
depth dose and profile algorithms fitted to Monte Carlo simulation data from a previous
study. Improvements to the version reported earlier were introduced, e.g. bone attenua-
tion was implemented. The applicability of the program to determine patient doses from
complex X-ray examinations (barium enema examination) was studied. The conversion
equations derived for female and male patients as a function of patient weight gave the
smallest deviation from the actual patient doses when compared to previous studies.
Another computer program, Intdose, was presented for calculation of the dose dis-
tribution from radiopharmaceuticals. The calculation is based on convolution of an iso-
tope specific point dose kernel with activity distribution, obtained from single photon
emission computed tomography (SPECT) images. Anatomical information is taken from
magnetic resonance (MR) or computed tomography (CT) images. According to a phan-
tom study, Intdose agreed within 3 % with measurements. For volunteers administered
diagnostic radiopharmaceuticals, the results given by Intdose were found to agree with
traditional methods in cases of medium sized patients. For patients undergoing systemic
radiation therapy, the results by Intdose differed from measurements due to dynamic
biodistribution of the radiopharmaceutical since the calculation was based only on one
set of SPECT images.
In general, traditional methods using average sized calculation phantoms are in-
tended to give average doses for an exposed population. For calculating doses to indi-
vidual patients, patient specific calculation methods, e.g. ones proposed in this thesis,
should be used.
2CONTENTS
ABSTRACT 1
LIST OF PUBLICATIONS 3
NOMENCLATURE 4
AIM OF THE STUDY 5
1 INTRODUCTION 6
2 COMPUTING PATIENT RADIATION DOSES IN X-RAY
DIAGNOSTICS 10
2.1 Methods 10
2.2 Results and findings 14
3 CALCULATING INTERNAL PATIENT RADIATION DOSE IN
NUCLEAR MEDICINE 17
3.1 Methods 17
3.2 Results and findings 19
4 DISCUSSION 20
ACKNOWLEDGEMENTS 24
REFERENCES 25
ERRATA 31
3LIST OF PUBLICATIONS
This thesis is based on the following original publications, which are referred to in the
text by their Roman numerals, Publ. I-V.
I Rannikko S, Ermakov I, Lampinen JS, Toivonen M, Karila KTK, Chervja-
kov A. Computing patient doses of X-ray examinations using a patient
size- and sex-adjustable phantom. British Journal of Radiology 1997; 70:
708-718.
II Lampinen JS, Rannikko S. Patient specific doses used to analyse the opti-
mum dose delivery in barium enema examinations. British Journal of Radi-
ology 1999; 72: 1185-1195.
III Vehmas T, Lampinen JS, Mertjärvi A, Rannikko S. Factors influencing
patient radiation doses from barium enema examinations. Acta Radiologica
2000; 41: 167-171.
IV Lampinen JS, Pohjonen HK, Savolainen SE. Calculating internal dose by
convolution from SPECT/MR fusion images. Annals of Nuclear Medicine
1998; 12: 1-5.
V Aschan AC, Toivonen MJ, Lampinen JS, Tenhunen M, Kairemo KJA,
Korppi-Tommola ET, Jekunen AP, Sipilä P, Savolainen SE. The use of TL
detectors in dosimetry of systemic radiation therapy. Acta Oncologica
1999; 38: 189-196.
4NOMENCLATURE
A Activity [Bq]
AP Anteroposterior projection
ALARA As low as reasonably achieved
BEIR Committee on the Biological Effects of Ioninizing Radiation
CT Computed tomography
DAP Dose-area product [Gy⋅cm2]
E Effective dose [Sv]
 Effective individual dose [Sv]
Ep Photon energy [eV]
EC European Commission
EGS4 Electron-Gamma Shower v. 4
ESD Entrance surface dose [Gy]
FFT Fast Fourier transform
gcc Gnu Project C Compiler
HVL Half value layer
ICRP International Commission on Radiological Protection
in vivo In the living thing (Latin)
Ka Air kerma (kinetic energy released in matter) [Gy]
LAT Lateral projection
MCNP A General Monte Carlo N-Particle Transport Code
MIRD Medical Internal Radiation Dose Committee
MoAb Monoclonal antibody
MR Magnetic resonance
PA Posteroanterior projection
PCXMC PC program for X-ray Monte Carlo
ROI Region of interest
SPECT Single photon emission computed tomography
SRT Systemic radiation therapy
TL Thermoluminescent
VMC The Voxel Monte Carlo Code
5AIM OF THE STUDY
The aim of this thesis is to describe methods developed for patient specific radiation
dose calculations and to demonstrate their use in clinical X-ray examinations and nuclear
medicine applications.
The specific aims of the thesis are:
1) to develop a computer application using a patient size- and sex-adjustable phantom
for calculating patient specific organ doses from X-ray examinations,
2) to demonstrate the use of the developed application for investigating patient doses,
presenting barium enema examination as an example,
3) to develop a computer application using SPECT/MR fusion images and the convolu-
tion method for calculating patient specific dose distributions for patients administered
radiopharmaceuticals,
4) to apply the developed computer program for calculating dose distributions in patients
undergoing systemic radiation therapy.
61 INTRODUCTION
The knowledge of the absorbed radiation dose to the organs of a patient undergo-
ing a procedure involving radiation is essential in order to evaluate the detriment of the
procedure. The knowledge of the detriment is needed to evaluate the net benefit from the
procedure. The net benefit shall be sufficient in order to regard the exposure as justified
(ICRP 1991, EC 1997). In addition to the requirement of net benefit, the exposures
should be optimised, i.e. the magnitude of individual doses should be kept as low as rea-
sonably achieved (ALARA). The ALARA principle has different interpretations in di-
agnostics and therapy. In diagnostics, the ALARA principle means that the radiation
burden to the patient should be as low as reasonably achieved consistent with obtaining
the required diagnostic information (EC 1997). In radiation therapy, exposures of target
volumes shall be individually planned and the doses of non-target volumes and tissues
shall be optimised to be as low as reasonably achieved (EC 1997).
The desired quantity in patient dosimetry is the absorbed dose distribution in the
patient. Because of practical reasons mean absorbed doses to organs, i.e. organ doses are
used. According to present understanding, the radiation-induced detriment can be as-
sessed from the known organ doses (ICRP 1991). In current European legislation (EC
1997) the quantity describing overall risk from exposure to radiation is the effective
dose, E [Sv] (ICRP 1991). E is determined from organ doses and organ specific, radia-
tion risk related, weighting factors. The weighting factors of the effective dose are de-
rived as an average for the whole population. The weighting factors and the rules for
using them are based on scientific data, available mainly from atom bomb survivors in
Hiroshima and Nagasaki. The International Commission on Radiological Protection
(ICRP) has issued the latest definition of the weighting factors in 1995 (ICRP 1995). In
addition to tissue weighting factors, the effective dose also includes radiation quality
factors. Different radiation qualities induce different biological effects as the radiation
interacts with tissues. For photon radiation the quality factor is unity (ICRP 1991).
The Committee on the Biological Effects of Ioninizing Radiation (BEIR), assigned
by the National Research Council in USA, has published reports about the health effects
of ionising radiation. The latest report is known as BEIR V (BEIR 1990). The committee
has not given a quantity comparable to E, but they sum up organ and tissue specific risk
assessments. Important aspects of these risk assessments are the sex and age of the indi-
viduals. The methodology presented in BEIR V may be used to calculate a statistical
estimate of fatal cancer cases caused by exposures to radiation if the organ doses and
age distribution of the exposed individuals and local cancer and life expectancy statistics
are available.
In routine radiological procedures, it is not practical to conduct in vivo measure-
ments of organ doses. The possible practical methods for deriving the organ doses are
measurements in a phantom (see e.g. Toivonen et al. 1996), i.e. an artificial object repre-
senting a patient, or computer calculations. An important method applicable to a wide
range of applications is Monte Carlo simulation, which was introduced for the first time
7by Buffon in 1777 to estimate the value of pi (Schroeder 1974). The Monte Carlo simu-
lation has been widely adopted to radiation physics (for its applications in medical ra-
diation physics, see e.g. Andreo 1991). In a radiation physics simulation a virtual image
of the exposure conditions is modelled to a computer program, which then creates virtual
radiation particles and simulates interactions between the particles and the medium. The
particle tracks are followed from the source to their final absorption. Possible interac-
tions with matter are induced with random numbers and known probabilities of each
interaction type. The Monte Carlo simulation method itself is well documented and veri-
fied against measurements. Several Monte Carlo application packages are readily avail-
able. The present choices of the research community include e.g. EGS4 (Electron-
Gamma Shower) by Nelson et al. (1985), MCNP (A General Monte Carlo N-Particle
Transport Code) (Briesmeister 1997) and VMC (The Voxel Monte Carlo model)
(Kawrakov et al. 1996) applications, for which the user provides their own geometry and
sources. The packages provide the algorithms needed for radiation transport simulation.
Monte Carlo simulation is the established method for determining patient radiation
doses both in X-ray and nuclear medicine diagnostics. The basic phantom model used in
these simulations is the hermaphrodite MIRD (Medical Internal Radiation Dose Com-
mittee, assigned by the Society of Nuclear Medicine) phantom, originally developed for
use in estimates of internal dose (Snyder et al. 1969). The body contour and the organs
of the MIRD phantom are defined with geometrical shapes. The MIRD phantom has
since been improved, i.e. new organs have been included (Jones et Wall 1985) and sexes
have been separated (Kramer et al. 1982). Special phantoms have been developed to
model children at different ages (Cristy 1980). The basic concepts of all these modifica-
tions to the MIRD phantom are similar to each other, they are all based on mathematical
shapes. In addition to mathematical phantoms, phantoms based on actual human ana-
tomical data from computed tomography (CT) or magnetic resonance (MR) images may
also be used in Monte Carlo simulations (Tagesson et al. 1996, Furhang et al. 1996a,
Furhang et al. 1997, du Plessis et al. 1998).
The use of the Monte Carlo method for organ dose calculation in X-ray diagnos-
tics was introduced by Rosenstein, who using a MIRD based phantom calculated doses
to five organs for adult (Rosenstein 1976) and paediatric (Rosenstein et al. 1979) X-ray
examinations. Drexler et al. (1984) used the sex-specific phantoms of Kramer et al.
(1982) to calculate organ doses in conventional X-ray examinations. Jones et Wall
(1985) used their phantom to calculate organ doses in 12 common X-ray examinations.
Hart et al. (1994) determined conversion coefficients from entrance surface dose (ESD)
and dose-area product (DAP) to organ doses using an improved phantom which included
all the organs needed for calculating the effective dose (ICRP 1991). They also pre-
sented conversion coefficients from the total DAP value of an examination for nine
complex X-ray examinations composed of several exposures; for example a coefficient
of 0.28 mSv/Gy⋅cm2 was given for barium enema examination. Hart et al. (1996) have
also calculated conversion coefficients for estimating effective doses in paediatric X-ray
8examinations. Several front-end applications have been developed to simplify the use of
the conversion coefficient tables (e.g. EFFDOSE and CHILDOS1).
Monte Carlo simulation is time consuming. It is therefore practical to use pre-
calculated conversion coefficients from an easily measurable quantity to effective dose
or organ doses. In X-ray diagnostics this measurable quantity may be entrance surface
dose, ESD [Gy], air kerma, Ka [Gy] or dose-area product, DAP [Gy⋅cm2]. In diagnostic
nuclear medicine administered activity, A [Bq], is used. The conversion coefficients are
derived for a phantom representing an average patient. Therefore, the organ doses de-
termined with conversion coefficients represent average doses for a large population,
which in fact are needed to calculate the effective dose as defined by ICRP.
The conversion coefficients apply only to the pre-calculated conditions, i.e. expo-
sure geometry, radiation spectra and patient size. The end-user is able to estimate the
organ and effective doses without using the Monte Carlo application itself. Tapiovaara
et al. (1997) have presented a more flexible Monte Carlo application, in which the end-
user is able adjust the exposure geometry, radiation spectra and patient size. The basic
phantom is selected from six mathematical hermaphrodite phantoms (adult, 15, 10, 5 or
1-year old) by Cristy (1980), which may then be adjusted in size according to the patient
in question. The results of the time consuming radiation transport simulation of one par-
ticular exposure geometry may be used to calculate organ doses for any spectra, which
makes it simple to compare the effects of different radiation qualities.
In dosimetry of nuclear medicine where absorbed doses to organs from radiation
emitting from internal sources are of interest, the calculation is based on S-values. The
methodology was originally developed by Loevinger et Berman (1968) and it was im-
plemented to practice in a MIRD pamphlet (Snyder et al. 1975). Traditionally an S-value
describes the absorbed dose to a specific target organ from radiation emitting from an-
other specific source organ. An S-value defined at the organ level assumes that the ac-
tivity inside the source organ is homogeneously distributed. The organ level S-values are
derived using Monte Carlo methods and MIRD phantom. S-values have recently been
developed to be applicable also to dosimetry at the suborgan, voxel, multicellular and
cellular levels (Howell et al. 1999, Bolch et al. 1999). Organ level S-values for common
radiopharmaceuticals used in nuclear medicine diagnostics are published by ICRP
(1987). The data has been calculated assuming that the biodistribution of the radiophar-
maceuticals in the patients, i.e. the distribution of the injected substance in the organs
and tissues, behaves as for an average human. Patient specific properties of the biodis-
tribution are ignored. Several computer applications have been developed to simplify the
use of S-values, i.e. MABDOS (Johnson 1988) and MIRDOSE3 (Stabin 1996).
Different approaches to the use of Monte Carlo simulations to benefit patient dose
calculations are demonstrated in Publ. I and IV. In Publ. I analytical algorithms are fitted
to dose distribution data from extensive Monte Carlo simulations where a water phantom
was exposed to various X-ray spectra (Tapiovaara 1983). The algorithms are then used
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9to calculate the dose distribution in an anatomical phantom. The anatomical phantom is
sex-specific, and its size is adjusted to match the size of the patient (Servomaa et al.
1989). This technique is fast, since the results from time-consuming simulations are re-
shaped to flexible equations. In Publ. IV point dose kernels describing the dose distribu-
tion from a point source for selected isotopes were convoluted with the activity distribu-
tion to get the absorbed dose distribution. The activity distribution is obtained from
SPECT (single photon emission computed tomography) images of the patient in ques-
tion. The organ doses of the patient were derived from the absorbed dose distribution
using MR (magnetic resonance) images for the patient's anatomical information. The
convolution process is again fast compared to the simulation and verified kernels are
available in the literature (Furhang et al. 1996b).
The use of the methods introduced in Publ. I and IV are demonstrated in Publ. II,
III and V. Patient specific organ and effective doses of 89 barium enema X-ray exami-
nation patients are calculated as an example of the capabilities of the computer program
described in Publ. I. In addition to reporting the calculated doses in Publ. II and III, new
aspects of analysing dose delivery (Publ. II) and factors influencing the patient dose
(Publ. III) are considered. In Publ. V the computer program introduced in Publ. IV is
applied to calculate dose distributions and doses to some organs of six patients under-
going systemic radiation therapy (SRT). The doses calculated with the patient specific
method and input data are compared with the doses calculated with conversion coeffi-
cients. Some unpublished methods and results are also presented. Improvements to the
computer program described in Publ. I are reported.
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2 COMPUTING PATIENT RADIATION DOSES IN X-RAY
DIAGNOSTICS
A computer program, later referred to as ODS-602, which is able to calculate pa-
tient specific organ doses from X-ray examinations was developed (Publ. I). ODS-60 is
a combination of two modules, a size- and sex-adjustable phantom model and a collec-
tion of algorithms to calculate the absorbed dose to an arbitrary point in the phantom.
The program code was written in standard C language and compiled with Gnu Project C
Compiler (gcc). A user interface (Lampinen et al. 1996) was developed with Visual Ba-
sic 4.03.
The phantom model (Servomaa et al. 1989) is based on an anatomical Alderson-
Rando phantom4 and an anatomical atlas (Symington 1956). The basic phantom repre-
sents a male of 173 cm in height and 73.5 kg in weight. The phantom is constructed from
slices, for which the body and organ contours are described with points. A line connect-
ing the points of each shape defines the contour of that shape. The co-ordinates of each
point are transformed to correspond to the patient’s size. A female phantom is con-
structed from the male phantom by changing the description of the chest and pelvic re-
gions to correspond to female anatomy.
2.1 Methods
The absorbed doses to the organs in the ODS-60 program are calculated using
Monte Carlo-simulated dose distributions for a semi-infinitive, 30-cm thick water slab
(Tapiovaara 1983). Mathematical equations, representing relative depth dose and dose
profiles, are used to calculate absorbed dose at an arbitrary point in the above mentioned
semi-infinitive water slab. The phantom is positioned in the slab according to the expo-
sure geometry, i.e. projection and position of the X-ray field on the patient’s skin. The
program divides the organs into 1 cm ⋅ 1 cm ⋅ z cm (z being the slice thickness) sized
voxels for which the absorbed doses are calculated. The organ dose is the average ab-
sorbed dose in the voxels of an organ. The effective dose is calculated using the ICRP
weighting factors, but since the phantom is sex-specific, ovary, uterus and breast doses
are available only to females and testis dose only to males. The absorbed dose to the
fetus is not calculated, but may in the early stages of pregnancy be estimated from the
uterus dose.
All materials in the phantom, in the program version reported in Publ. I, are as-
sumed to be water with the exception of lung tissue. The lung tissue is assumed to be
otherwise similar to water, but only 0.3 g/cm3 in density. Therefore, an adjusted depth
value is used in the depth dose and dose profile equations in the case of a voxel which
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has lung tissue between the voxel and focus of the X-ray tube. Also, the attenuation ef-
fect of the pelvic bone is taken into account with a correction factor, but only in the case
of the uterus and ovaries.
The ODS-60 program has been further developed by the author after the first in-
troduction in Publ. I. Several minor modifications and fixes were implemented. The
backscatter factor function (equation 7 in Publ. I) was corrected to correspond to a rec-
tangular field, as the original data by Grosswendt (1990) was derived for circular fields.
The correction is done by multiplying the effective area of the field (equation 7 in Publ.
I) by 0.9 (Day et Aird 1983).
The discontinuity of the backscatter factor as a function of X-ray tube voltage
(shown clearly in e.g. figure 6 in Publ. I) was removed. Precisely speaking the backscat-
ter factor is a function of the half value layer (HVL) value. The correction uses the same
non-continuous functions as before, but in the vicinity of the cut-point (HVL value of 4
mm Al) an interpolation between these two functions is made.
Some organs were redefined. The contribution of the contents of the stomach, in-
testines and bladder to the average organ dose is no longer considered. The absorbed
dose to eyes was defined separately for both eyes. The definition of the colon is select-
able according to either ICRP (1991) or ICRP (1995). The density correction for lung
tissue was removed.
In addition to these minor modifications, a skeleton was modelled and imple-
mented to the ODS-60 phantom (Figure 1). The skeleton consists of a skull, spine, rib
cage and pelvic bone. The properties of the skeleton have been derived from the specifi-
cations of the adult MIRD phantom (Cristy 1980) and the description of the anatomical
phantom (Servomaa et al. 1989) on which the ODS-60 phantom is based. The shapes of
Figure 1. The body contour of the basic phantom model of the ODS-60 and the skeleton
developed for him.
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the bones are derived from Servomaa et al. (1989) and the thickness values from Cristy
(1980). The skull covers the brain of the phantom with a 0.9-cm thick homogeneous
layer. The spine was defined as an ellipse whose thickness is calculated separately for
each calculation voxel (i.e. the spine thickness along the ray from X-ray focus to the
voxel). The rib cage is a homogeneous 0.25-cm thick layer, derived from the 0.5-cm
thick ribs of the MIRD phantom. The pelvic bone is a 0.7-cm thick arc in the posterior
side of the phantom.
For simplicity, the depth dose and profile equations for the 30-cm thick water slab
(from Tapiovaara (1983)) with a simple correction are used when calculating absorbed
doses behind bone material. The correction method is derived from the physics of nar-
row beam geometry, i.e. scatter is neglected. In narrow beam geometry, the exponential
attenuation equation
I/I0 = exp[-(µ/ρ) ρ t] (1)
gives the intensity I emerging from a layer of material with thickness t and density ρ
assuming an incident intensity of I0. The mass attenuation coefficient µ/ρ(Ep) [cm2/g]
describes how a certain material attenuates primary radiation photons as a function of
photon energy, Ep (Attix 1986). The depth dose equations used in ODS-60 are based on
broad beam geometry simulation and the depth dose data includes knowledge about how
water attenuates broad beam radiation, i.e. when a scatter component is included. The
correction made for bone attenuation is based on an assumption that formalism derived
for narrow beam geometry is also applicable for broad beam geometry. In practise, the
correction for voxels behind bone material is implemented by recalculating the depth, t,
from bone thickness tbone and the actual depth of the voxel t0 as
t = t0 + β tbone (2)
where β is an experimental coefficient given as a function of X-ray spectrum. Two pa-
rameters are embedded in β, the difference of µ/ρ of water to that of bone (Hubbell et
Seltzer 1997) and the ratio of the densities of bone and water (1.50) (Cristy 1980). The
difference in µ/ρ is due to the different atomic composition of the two substances and it
is a function of photon energy. The coefficient β was derived from dose distributions
produced with Monte Carlo simulations.
An MCNP (Briesmeister 1997) application was used to simulate dose distribution
in water with and without a slice of bone of variable thickness (5, 10 or 20 mm). Mono-
energetic (20, 30, 40, 50, 60, 70, 80, 90 and 100 keV), non-divergent, 15 x 15 cm sized
photon beams were directed towards a cubical (30 x 30 x 30 cm) phantom. The phantom
consisted of either pure water or of water and a layer of bone material at a depth of 10
mm in the phantom, measured from the direction of the beam entrance. Depth dose dis-
tribution was recorded in 1 x 1 x 1 cm sized voxels using a pulse height tally *F8 [MeV]
(Briesmeister 1997).
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A specific value of β, βi, was derived for each monoenergetic (energy Ei) photon
beam. Each βi value was derived by first fitting a rational function to the simulated depth
dose curve (without bone) and then finding the required horizontal shift for that curve in
order to produce a curve similar to the depth dose curve simulated with the 10 mm-thick
bone layer. The amount of horizontal shift was optimised to give an average ratio of 1.00
for the depth dose curves (the one simulated with bone and the one produced with the
shift) in the depths from 3 cm to the tenth value layer thickness. The sum of βi over all
energies Ei of the X-ray spectrum, weighted with the photon yield for each energy group
is then used to calculate a value of β for an arbitrary spectrum.
The exit dose calculated by ODS-60 is defined according to narrow beam geome-
try. The exit dose is calculated with the exponential attenuation equation (equation 1),
mass attenuation coefficients for tissue and bone (Hubbell et Seltzer 1997) and X-ray
spectrum calculated for the exposure in question (Boone et Seibert 1997).
Double contrast barium enema X-ray examination is the largest single contributor
(14%) to the annual collective effective dose in Finland (Rannikko et al. 1997). During
the examination the patient's large intestine is first filled per rectum with barium contrast
medium, which is then removed and replaced with air to achieve both negative and posi-
tive contrast effects. The examination procedure contains both radiographs and fluoros-
copy which makes calculating the patient dose very challenging.
The patient specific organ and effective doses were derived for 89 barium enema
examination patients in five hospitals in order to find out the variation in the effective
dose (Publ. II) and the reasons for the variation (Publ. III). The ODS-60 program was
used in the organ dose calculations. The bone correction method of the program version
used in the calculations of Publ. II and III was not exactly the same as described in the
previous chapter. The earlier version of the correction was based on bone thickness and
an averaged photon energy effect.
Registering all the parameters required for dose calculation with ODS-60 needed
the full attention of two dedicated people. The static parameters registered were patient
size (length and weight) and sex and X-ray tube filtration. Parameters changing during
the examination were the size (height and width), location and projection of the X-ray
field, focus-skin distance, tube voltage, exposure time and current.
Due to the definition of the effective dose, i.e. it is not to be used as a radiation
risk related quantity for an individual person, a new quantity, effective individual dose,
 [Sv], was introduced in Publ. II. This new quantity is calculated as the effective dose,
but the weighting factors for sex specific organs are reassigned, i.e.  is a sum of those
organ doses and corresponding weighting factors, which are present according to pa-
tient's sex.
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2.2 Results and findings
A demonstration of the abilities of the bone correction method described above is
presented in figure 2. The effect of the skeleton in the exit dose, i.e. the primary part of
the radiation penetrating the phantom, calculation is demonstrated in figure 3 of Publ. II.
In comparison with experimental dose determinations in an Alderson-Rando
phantom with TL dosimeters (Toivonen et al. 1996), the doses calculated with ODS-60
converg towards the measured ones as the program has been improved. When comparing
the effective doses calculated with the ODS-60 version based on the bone correction
method described in this thesis, the differences between calculations and measurements
are 10 %, 18 % and 2 % for chest posteroanterior (PA), abdomen anteroposterior (AP)
and modified lumbar spine lateral (LAT) projections, respectively. Table I summarises
the comparison of doses calculated with different ODS-60 versions to the measured
doses.
The ability to use a patient specific dose calculation method provides the means to
draw a correlation between patient doses and patient characteristics, i.e. size and sex.
The benefit from using the patient specific doses can be seen from figure 2 in Publ. II,
where the conversion from dose-area product, DAP, to  is presented as a function of
patient sex and weight. The equations obtained for the conversion were
/DAP = 0.92 e-0.0154 weight (3a)
/DAP = 0.56 e-0.0154 weight (3b)
Figure 2. The graph on the left shows the correction method applied to an X-ray spec-
trum (Birch et al. 1979) for 100 kV of tube voltage and 3 mm Al of filtration and a 10-
mm thick bone layer. On the right, the correction method applied for different bone
thickness is shown (50 keV monoenergetic beam). In both figures, the lines represent
the depth dose curves derived using the correction method. Error bars in the left figure
indicate the statistical error of the Monte Carlo simulation.
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Table I. Comparison of effective doses calculated with different ODS-60 versions and
measured in an Alderson-Rando phantom. Effective doses [mSv] and the relative
difference of calculated and measured effective doses (in parentheses) are given.
Entrance surface doses used in the comparison do not correspond to real examinations.
Method Measured ODS-60 v1.0 ODS-60 v2.0 ODS-60 v2.1
Reference Toivonen et
al. (1996)
Publ I Publ II this thesis
chest PA 21 25 (19 %) 23 (7 %) 19 (10 %)
abdomen AP 22 28 (27 %) 27 (23 %) 26 (18 %)
mod. lumbar spine LAT 10 11 (10 %) 10 (1 %) 9.8 (2 %)
where weight is given in kg, for females and males, respectively. The equations above
are derived from doses calculated for 89 adult patients and therefore should not be used
for paediatric patients. The phantom transformation (Servomaa et al. 1989) is valid from
40 to 110 kg and 140 to 200 cm sized patients.
In Table V of Publ. II, the /DAP [mSv/Gy⋅cm2] conversion was compared to a
conversion coefficient derived using a MIRD phantom by Hart et al. (1994) and to sex
specific conversion coefficients by Geleijns et al. (1997). The relative standard deviation
(S.D.) of the difference between doses derived from coefficients and the actual doses
was 39 % for 0.28 mSv/Gy⋅cm2 from Hart et al. (1994). For Geleijns et al. (1997) S.D.
was 27 % for females (0.33 mSv/Gy⋅cm2) and 25 % for males (0.20 mSv/Gy⋅cm2). The
relative standard deviation of the conversion using equations 3a and 3b was 16 % for
females (0.38 mSv/Gy⋅cm2 for 58 kg) and 21 % (0.19 mSv/Gy⋅cm2 for 70 kg) for males.
In general, the mean and median of the differences between patient specific doses and
those obtained with different conversion coefficients or functions are comparable with
each other. This indicates that all calculation methods deliver similar doses for an aver-
age patient.
The factors behind the variation of the doses of the 89 barium enema patients were
analysed in Publ. III. The median effective doses in the five hospitals were 4.4, 6.1, 7.1,
13 and 16 mSv. When compared with each other, the effective dose distributions in the
hospitals were significantly different. Only the E in one hospital was not different from
E in three others due to a wide distribution of E in that hospital. The correlation analysis
showed that 40 % of the variation could be explained with radiologist controlled factors,
i.e. screening time and number of exposures. Only 16 % of the variation was related to
patient characteristics, i.e. patient weight and height, sex and age. The residual 44 %
includes e.g. the equipment-related factors.
An interesting finding in the correlation analysis was that both patient’s weight
and height correlated negatively with effective dose. This phenomenon was studied in
Publ. II where the functionalities of the exposure control equipment in the hospitals were
analysed theoretically. Our findings were in agreement with an earlier result by Rowley
et al. (1987) that the exposure control equipment is reaching the limits of its capability at
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the extremes of patient weights. Even for an individual patient the exposure control may
deliver exposures with hundred-fold differences.
The great variation of exposures indicates that exposure control equipment is not
used optimally, i.e. either bone or contrast media (barium) is disturbing the measurement
sensor of the exposure control. This should be avoided by using those measurement sen-
sors that are not shadowed by bone or contrast media.
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3 CALCULATING INTERNAL PATIENT RADIATION DOSE IN
NUCLEAR MEDICINE
A computer program, later referred to as Intdose, was developed to calculate ab-
sorbed dose distribution in patient administered radiopharmaceuticals for diagnostic or
therapeutic purposes. The calculation is based on a convolution process implemented
with a Fast Fourier transformation (FFT) in 3 dimensions. The program code was writ-
ten in standard C language and compiled with Gnu Project C Compiler (gcc).
Images from two distinct imaging modalities are needed in order to calculate ab-
sorbed dose distribution in the patient and to use the distribution to calculate the mean
absorbed dose to an organ. In single photon emission computed tomography (SPECT)
multiple acquisitions from the region of interest (ROI) are registered from different an-
gles. These planar views are then used to construct a 3 dimensional count matrix relative
to the activity distribution in that volume. The count matrix is then converted to an ac-
tivity matrix by some quantification method. Magnetic resonance (MR) or computed
tomography (CT) images of the patient are also needed, because SPECT images do not
contain direct anatomical information. The SPECT and MR or CT images must be pre-
sented in the same co-ordinate system; i.e. the images must be registered.
3.1 Methods
The Intdose has two separate modules, the first calculating dose distribution in the
co-ordinate system (matrix) of the images and the second calculating the mean absorbed
dose in the voxels of each organ. The calculation of the dose distribution is based on
convoluting the activity matrix with a point dose kernel matrix. The point dose kernel
describes how radiation absorbs to a medium as a function of distance from a point
source of certain isotope per one decay. Point dose kernels are produced with Monte
Carlo simulations and have been published by e.g. Furhang et al. (1996b). The result of
the convolution process is an activity distribution weighted sum of point dose kernels,
i.e. the dose rate distribution. A straightforward convolution of two e.g. 128x128x128
(about 2⋅106 voxels) sized matrices would be an enormous task. A novel method to
achieve the same result is to use Fast Fourier transform (FFT). The concept of the Fou-
rier transform is that convolutions in one space correspond to multiplications in the re-
ciprocal space (Webb 1988). Using FFT, the calculation of the dose date distribution
dD/dt(r) may be formulated as
dD/dt(r)=FFT-1[FFT{A(r)}⋅FFT{K(r)}] (4)
where A(r) is the activity distribution, K(r) is the point dose kernel and the notation
FFT-1 means the inverse of Fast Fourier transform. The dose rate distribution may sub-
sequently be converted in to a dose distribution, D(r), by using the physical half-life of
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the nuclide in question. The dose contribution from β-decays (Browne et al. 1986) was
assumed to be local within the source voxels.
A phantom study was carried out to compare the absorbed doses measured with
thermoluminescent (TL) detectors and those calculated with Intdose (Publ. V). The
phantom was an elliptical water phantom5 with a cylindrical 131I source. The activity
distribution was generated by hand to correspond to the known location (focal point or
centre of the phantom), dimensions (diameter 5.3 cm and height 8 cm) and activity (3000
MBq) of the source.
The clinical applicability of Intdose was demonstrated in Publ. IV by calculating
absorbed doses to liver and spleen for three healthy volunteers administered two com-
mon radiopharmaceuticals used in diagnostics. The volunteers were first administered
111In-oxine-labeled thrombocytes and two days later 99mTc-labeled tin colloids (Pohjonen
et al. 1996). The MR images of the volunteers were registered with SPECT images de-
scribing the count distribution after the administration of each radiopharmaceutical. The
MR images were segmented to identify the spleen and liver. The imaging and registra-
tion protocols are described in detail by Pohjonen et al. (1996). The errors associated
with the registration procedure used in Publ. IV are discussed by Sipilä et al. (1997). The
local ethical committee approved the study and informed consent was obtained from all
volunteers. The activity distribution was calculated from the count matrix by assuming
that all activity was present in the imaged volume and that the activity in each voxel was
linearly dependent on the number of counts.
As part of a study describing a method for determining absorbed doses to organs
in systemic radiation therapy (SRT), doses to patients’ kidneys were calculated using the
Intdose program (Publ. V). The method described was based on thermoluminescent (TL)
detectors placed on the patient’s skin. Doses to the kidneys of six patients treated with
SRT were determined with the TL method, Intdose and MIRD formalism (MIRDOSE3
program).
The SRT patients had large intraperitoneal disease (pseudomyxoma) with no exact
tumour volume. The patients were administered 131I-ladeled monoclonal antibody
(MoAb) intraperitoneally. CT and SPECT images were taken from the abdominal area of
the patients. SPECT imaging was performed at 3, 10 and 24 days after injection.
The count matrix used in the dose distribution calculation by Intdose was taken
from the third-day SPECT images. All the activity administered was assumed to be lo-
cated in the volume covered by the SPECT images. The CT and SPECT images were not
registered and external markers to enable this were not used. The images were trans-
formed to the same co-ordinate system by hand using i.e. scout images. Also, the origi-
nal CT images, which consisted of 1 cm thick 256x256 slices (pixel size 2.0x2.0 mm),
were transformed to equal the format of the SPECT data (9.34 mm thick 64x64 slices
with pixel size of 5.76x5.76 mm). The point dose kernel for 131I was taken from Furhang
et al. (1996b). Although the CT and SPECT images were presented in a 64x64x64-sized
                                                
5
 Data Spectrum Corporation, Hillsborough, North Carolina, USA
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matrix, they were embedded in 128x128x128-sized zero matrixes in order to prevent the
folding of the Fourier transform (Press et al. 1992).
3.2 Results and findings
According to the phantom study in Publ. V, Intdose agreed within 3 % with the
measurements inside the water phantom. The phantom calculation used ideal and known
activity distribution and therefore did not have the uncertainties of the SPECT activity
quantitation present. The resulting 3 % difference between the measurements and calcu-
lations may be regarded as proof of applicability of the convolution method.
In Publ. IV the mean absorbed doses to livers and spleens of the volunteers calcu-
lated with Intdose were compared to those given in ICRP Publication 53 (ICRP 1987).
On average, the results were in good agreement, as can be seen from table 1 in Publ. IV.
In case of 99mTc, the difference of the mean absorbed dose to liver per activity adminis-
tered, calculated by Intdose and given by ICRP (1987) is 8 %. In case of 111In and
spleen, the difference is 20 %. Variation in the patient specific doses to the organs of the
volunteers is explained with variable organ sizes.
In addition to organ doses, the S-values S(liver-spleen), S(liver-liver), S(spleen-liver) and
S(spleen-spleen) were also calculated and compared to those given by MIRDOSE3 (Stabin
1996). In general, the S-values agree well in cases where the target organ is also the
source, i.e. S(liver-liver) and S(spleen-spleen). For 99mTc, the average S(liver-liver) and S(spleen-
spleen) calculated by Intdose differ by 7 % and 3 %, respectively, from those given by
MIRDOSE3. For 111In, the corresponding differences are 3 % and 25 %. In other cases
the agreement is within the order of magnitude. The differences in S-values are also
mainly due to different organ sizes. For example, the ratio of the spleen sizes of volun-
teers 2 and 3 is 2.8 (Pohjonen et al. 1996).
For kidney doses of eight SRT patients, a general trend between the doses deter-
mined with the TL method and those calculated with either Intdose or MIRDOSE3 was
that the calculated doses were higher. Calculated (Intdose) absorbed doses to the right
kidney varied from 89 to 235 µGy/MBq (mean 158 µGy/MBq) and correspondingly
from 89 to 216 µGy/MBq (mean 157 µGy/MBq) to the left kidney. The doses were, on
average, 93 % and 100 % higher than those derived with the TL method. The residence
times used in the calculations were taken from daily gamma images. According to gam-
ma images, the average effective half-live of the radiopharmaceuticals in the peritoneal
cavities of the patients was 27 hours (physical half-life of 131I is 8.04 days). The calcula-
tions were done on the basis of the activity (count) distribution on the third day. Even
though the patient specific effective half-lives were used, the assumption of a constant
activity distribution was not adequate. A better result would require using more than one
set of SPECT images in the calculations. On the other hand, the overall uncertainty of
the TL method was 46 % (1 standard deviation). As concluded in Publ. V, in terms of
dose calculations, 131I is a sub-optimal choice for systemic radiation therapy.
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4 DISCUSSION
Two computer programs aimed for patient dosimetry purposes and their applica-
bility in clinical examinations were presented in this thesis. Both programs calculate
organ doses for individual patients using patient specific calculation phantoms.
Awareness of the risks associated with ionising radiation has lead to a need to es-
timate these risks at the level of an individual patient. It is remarkable that there is no
such quantity defined, which could be used to characterise radiation detriment for an
individual patient. The effective dose, E, is intended for radiation protection purposes
only and should not be used for individual patients. The weighting factors are statisti-
cally derived from a large population. The properties of individual patient's organs and
tissues may differ from those of a large population. It is impossible to determine indi-
vidual weighting factors, i.e. quantities related to individual probabilities for radiation-
induced cancer or genetic alteration. It is, however, possible to derive weighting factors
for smaller sub-groups, for example for females and males separately as well as for chil-
dren and adolescents (Almén et Mattsson 1996). These dependencies have also been
considered in the BEIR V report (BEIR 1990).
The effective individual dose  introduced in Publ. II uses the same values for
weighting factors as the effective dose E does. The only difference between these two
quantities is that the contribution of those organs not present in the sex-specific phantom
is not accounted for. Therefore,  does not include any additional patient specific factors
but sex. In order to include the effect of e.g. patient's age into , new weighting factors
including these dependencies are needed. However, a simple modification to the values
of the present weighting factors may be used to estimate the radiation-related risk to the
non-fertile patients. For this group, only somatic risk is relevant, i.e. genetic risk may be
neglected. An example of this is given in Publ. II, where sex specific risk estimates, as-
suming that the patients are not fertile, are also given for barium enema examination
patients.
Conversion coefficients are useful tools for making estimations about the organ
and effective doses from an exposure. Since the effective dose is a quantity to be used in
population risk assessments, the input parameters used in conversion should also be av-
erages from a large number of examinations, i.e. corresponding to an average examina-
tion procedure. One application of these whole population averaged effective doses is
the determination of collective doses. The effective doses resulting from the conversion
are valid for the phantom for which the conversion coefficient has been derived. In case
of the MIRD phantom, its properties are considered to correspond to those of an average
human. Since the MIRD phantom was originally designed for dosimetry of internal
sources, its development has focused on correct centre-of-mass distances of different
organs instead of correct anatomical shapes or positions. When applied to dosimetry of
internal sources, the MIRD phantom is realistic. However, when applied to dosimetry of
external radiation with limited field sizes, the locations and shapes of the organs in rela-
tion to the radiation field are of importance.
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The concept of converting an easily measurable quantity to another quantity relat-
ing to radiation induced risk, is elegant. To improve the accuracy of the presently used
MIRD phantom based conversion coefficients (e.g. Hart et al. 1994), the conversions for
simple X-ray examinations should be re-determined from limited patient samples using a
patient specific calculation method, e.g. ODS-60 program presented in this thesis. As an
example, conversion equations derived for barium enema examinations using ODS-60
(equations 3a and b), give about a 50 % smaller standard deviation for the ratio of the
actual and converted effective doses than the method using Monte Carlo simulation and
the MIRD phantom (Hart et al. 1994). For those examinations and procedures not fa-
vouring the use of simple conversion, because of highly individual exposures, one
should use the patient specific calculation application itself. Whether ODS-60, or any
other patient specific dose calculation method, is used for re-producing conversion
functions or for truly individual patient specific dose determination, the effective dose
should be redefined to allow the calculation of individual risk related quantity.
The main concern in radiation protection proclamation by ICRP has been focused
on the societal criteria, i.e. collective doses have been used to determine the optimum
spend on the control of a source (Clarke 1998). The discussion aimed to change this
approach to a more individual-based philosophy has been opened by R. Clarke (1998),
chairman of ICRP. The proposed schema includes a concept of a controllable dose,
which could be derived for individuals. The specific methods for determining, i.e. meas-
uring or calculating, these controllable doses are still unknown. Whatever the means of
determination are, the equation must include individual organ doses, if truly individual
radiation detriment related quantities are desired.
Organ doses are measurable quantities, at least indirectly, and may be determined
for individual patients. In practise, the measurement method must be based on recording
of the parameters of the exposure and some calculation algorithm to assess the organ
doses. The desired accuracy of the organ doses determines what requirements the details
of the recorded exposure parameters and patient characteristics must meet. For simple
examinations with small effective (individual) dose, i.e. a thorax posteroanterior (PA) X-
ray examination, it is adequate to estimate the dose with, for example, a DAP measure-
ment and a conversion coefficient or function. The main interest areas for accurate dose
determinations are the examinations and procedures with high doses, i.e. examinations
and operations using fluoroscopy screening, especially interventional radiology.
The manual recording of the exposure parameters needed for accurate organ dose
calculations of barium enema examinations required two dedicated people. Although
possible in scientific studies, it is naturally out of the question in clinical routine. There-
fore, as much of the recording should be automated as possible. A device measuring air
kerma, dimensions of the X-ray field and focus-skin distance, e.g. one proposed by Ran-
nikko et Helenius (1998), in addition to field location and projection sensing equipment
would be needed. The latter should be built internally to the X-ray equipment as well as
the sensors for X-ray beam quality.
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The problems in the dosimetry of radiopharmaceuticals are different from those of
external radiation. Once the radiopharmaceutical has been administered, it distributes in
the blood, tissues and organs of the patient. This biodistribution is highly patient spe-
cific. In fact, the diagnostic use of a radiopharmaceutical is based on observing the pa-
tient specific biodistribution and with knowledge of normal distribution, the physician is
able to assess the internal condition of the patient. In therapy applications the require-
ments for accurate dosimetry are emphasised, since the absorbed dose in the dose limit-
ing healthy organs must be kept below dose limits. In therapy, the biodistribution is even
more difficult to predict than in diagnostics, since the radiopharmaceutical is usually
labelled with a tumour specific antibody. Most of the radiopharmaceutical particles are
likely to attach to the tumour cells, but the behaviour of the remaining part is unknown,
it may, for example, circulate in the blood, concentrate to the thyroid or exit the system
through the urinary system.
Single photon emission computed tomography (SPECT) imaging provides a 3-
dimensional distribution of the measured counts. If this count distribution is to be used
in the calculation of the dose distribution in a patient, two requirements may be set to the
imaging protocol. First, the SPECT images should be registered with anatomical mag-
netic resonance (MR) or computed tomography (CT) images. Second, the count distri-
bution should be quantified in terms of absolute activity. The methods for image regis-
tration are already available for clinical use (e.g. Pohjonen et al. 1996). The methods for
absolute quantitation of SPECT images are available through attenuation and scatter
corrections (Ljungberg 1990), which could be practically implemented using e.g. trans-
mission imaging. In transmission imaging a multihead SPECT camera and a line source
are used to acquire a crude transmission tomograph image of the patient. The tomograph
is then used in the attenuation and scatter corrections. Kauppinen (1999) has presented
an up-todate discussion about the scatter and attenuation corrections and SPECT image
reconstruction.
Calculation applications for dosimetry of radiopharmaceuticals, as Intdose pre-
sented in this thesis, rely on accurate activity quantitation and image registration meth-
ods. The activity quantitation is the Achilles heel of all dose calculation methods using
SPECT data to determine the activity distribution. In this respect Intdose does not bring
new aspects to previous methods like MIRDOSE3 and S-values in general. The accuracy
of the dose distribution calculated with Intdose is in principle only limited by the accu-
racy of the activity distribution. As seen from the phantom measurement in Publ. V, in
calculations based on known activity distribution, the results agree with those from
measurements within 3 %. The benefit of using Intdose instead of pre-calculated organ
level S-values (e.g. ICRP 1987) is independence over pre-defined organs as sources and
targets. Also, organ level S-values assume homogeneous activity distribution in a source
organ and also the results are given as average absorbed doses in each organ.
In diagnostic imaging using radiopharmaceuticals it is not practical to obtain the
anatomical information of the patient from MR or CT images. Therefore, a simplified
version of the Intdose, calculating only dose distribution without corresponding ana-
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tomical information, could be used in diagnostic applications if some estimate about the
dose is needed. On the other hand, organ level S-values give in most cases adequate dose
estimations for diagnostic patients. The main future use for full monty Intdose using also
anatomical data is, without a doubt, in therapy applications where knowledge of the dose
distribution is essential.
Although the effective dose is a weighted sum of the organ doses, the concept of
mean absorbed dose in an organ may not be relevant in all occasions. A hot spot, i.e. a
high local absorbed dose deposition, in an organ may, even though the average organ
dose is low, cause necrosis in the organ. Examples of this are the acute radiation injuries
experienced from locally high skin doses in interventional X-ray procedures (see e.g.
Huda et Peters (1994), Vañó et al. (1998)). Because of the possibility for acute radiation
symptoms for skin, the conversion coefficient method of measuring the pure total DAP
value, without any information about field location, of an interventional procedure, is of
little value. Instead of the average organ doses, a peak absorbed dose value on patient’s
skin should be known. The ODS-60 program presented in this thesis is an example of
the software part of a method able to assess absorbed dose distribution on patient’s skin
as a side product of organ doses. Analogously, in dosimetry of radiopharmaceuticals,
Intdose may be used to examine the dose distribution in an organ to discover the hot and
cold spots.
The computer applications presented in this thesis, ODS-60 for dosimetry of X-ray
examinations and Intdose for dosimetry of radiopharmaceuticals, are practical solutions
to fulfil the growing demands for patient specific dosimetry. In practice, ODS-60 can be
used in two ways. First, to produce more realistic conversion equations for simple X-ray
examinations than the presently used conversion coefficients from Monte Carlo simula-
tions using a MIRD phantom. Second, to calculate individual patient specific organ and
effective doses in those X-ray examinations and procedures which involve non-standard
exposures making the use of conversion equations impracticable. As for Intdose, its use
is most advantageous in therapy applications. In radiopharmaceutical diagnostics the use
of the established organ level S-values is the practical solution to dose assessments. In
therapy, however, Intdose's ability to use patient specific activity distribution and ana-
tomical data in addition to the ability to examine the resulting dose distribution makes it
superior to pre-calculated S-values.
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